Mastek secures NHS England cybersecurity training contract for executive boards and SIROs
Mastek (NSE: MASTEK; BSE: 523704), a leading digital engineering and cloud transformation company, has secured a significant contract from NHS England to provide cybersecurity training for NHS Boards and Senior Information Risk Owners (SIROs). This initiative, undertaken in partnership with Templar Executives, underscores Mastek's ongoing commitment to strengthening cyber resilience within the UK's public healthcare sector.
Under this one-year contract, with an option to extend for another year, Mastek and Templar Executives will deliver highly specialised cybersecurity training tailored specifically for senior NHS leaders. The aim is to enhance the understanding of the evolving cyber threat landscape and equip executives with the tools to manage risks more effectively. This training will play a crucial role in safeguarding patient data, maintaining operational continuity, and supporting overall clinical and financial outcomes.
The programme will deliver targeted training modules for both SIROs and NHS executive Boards. SIRO training will focus on the responsibilities of Senior and Deputy SIROs, helping them improve cyber governance and resilience across their organisations. Simultaneously, board-level training will provide executive members with critical knowledge around cybersecurity legislation, leadership responsibilities, and strategic governance in a digital-first healthcare environment.
This partnership highlights Mastek's strategic focus on enabling digital trust and security across public sector organisations. As cyber threats continue to grow in complexity and scale, Mastek's collaboration with NHS England demonstrates its ability to deliver transformative solutions that protect critical infrastructure and support digital innovation within essential services.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Trump to force NHS to pay for wonder drugs
NHS patients have been given new hope of accessing wonder drugs previously blocked in Britain as Donald Trump pressures the health service to spend more with US suppliers. Ministers are understood to be reviewing the value-for-money rules that govern which drugs the NHS can buy, amid demands from the Trump administration for the UK to be more welcoming to US pharmaceutical companies. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. Earlier this week, The Telegraph revealed that this could result in the NHS paying more for US drugs to see off criticism of the differences in medicine prices between the two nations. However, it is understood that discussions include not only paying more for treatments already supplied on the NHS but also making it easier for US drug giants to sell their most cutting-edge treatments to the health service. It follows a wave of high-profile rejections of so-called 'wonder' drugs in recent years. The National Institute of Health and Care Excellence (Nice), which approves new NHS drugs for purchase, has blocked treatments including one which stopped the progression of Alzheimer's disease and another that doubled the life expectancy for terminal breast cancer patients. Nice has rejected them based on assessments of how long they would extend a patient's lifespan and improve quality of life. To qualify under Nice rules a new treatment must deliver one extra year of perfect health, or longer for less perfect health, for no more than £30,000. This figure has not increased in line with inflation since 1999. If it had, it would be just over £53,000. Nice has maintained that, to get approval for use on the NHS, medicines 'must not only provide benefits to patients but also represent a good use of NHS resources and taxpayers' money'. However, critics say a failure to raise the threshold in-line with inflation meant life-changing drugs were being blocked. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: 'There is growing evidence that it is becoming harder to bring new medicines to NHS patients. Increasingly, some new medicines may not be launched in the UK at all.' Companies including US giant Eli Lilly have said the regulator must rethink how 'value-for-money' is assessed. On Monday, a spokesman for the company said: 'The UK has historically focused on medicines as a cost to the NHS rather than evaluating their social and economic value.' Ministers are understood to be listening to demands from the industry for Nice to shake up its formula, with medicines such as AstraZeneca's breast cancer treatment Enhertu likely to be resubmitted for approval for NHS use if the formula is updated. Nice and AstraZeneca previously failed to reach an agreement over a price for the drug, which costs an estimated £118,000 per course of treatment. The NHS typically gets discounts, although the level is commercially sensitive. The Nice formula is being discussed after President Trump took a personal interest in the NHS issue. In trade documents between the US and UK, it said the NHS would review drug pricing to take into account the 'concerns of the president'. US officials are particularly concerned by an arrangement that sees companies pay revenue back to the NHS if costs rise faster than expected. Drug companies paid £3bn back to the NHS last year. In April, Wes Streeting, the Health Secretary, said he was proud that the UK had kept prices of medicines low. However, he admitted that the UK had become too focused on cost rather than the benefits in some cases. Mr Streeting said: 'We've moved from quite rightly trying to drive a good bargain on the price of drugs and treatment to a position where sometimes people view medicine spend as a dead weight cost'.
Yahoo
4 hours ago
- Yahoo
Assisted dying: Medical students voice opposition as some MPs urge vote delay
Hundreds of medical students have voiced their opposition to an assisted dying law, as dozens of Labour MPs called for this week's vote on the issue to be delayed. It is currently expected the Terminally Ill Adults (End of Life) Bill will have its third reading on Friday, with MPs voting to either send it through to the House of Lords or to stop it progressing any further. It would be the first vote on the overall Bill to take place since November, when the proposed legislation passed second reading stage by a majority of 55 on a historic day which saw MPs support the principle of assisted dying for England and Wales. But, days ahead of third reading, a group of Labour MPs opposed to the Bill have written to Commons leader Lucy Powell asking for more time to scrutinise a Bill they brand as 'perhaps the most consequential piece of legislation that has appeared before the House in generations'. They added that it 'alters the foundations of our NHS, the relationship between doctor and patient, and it strips power away from Parliament, concentrating it in the hands of future secretaries of state for health'. They also raised concerns that MPs might not have a copy of the final Bill by the time they vote, as some outstanding amendments will still be being considered on Friday morning. The MPs, including Dame Meg Hiller, wrote: 'We implore you as the Leader of the House to allocate more Parliamentary time to the scrutiny of this Bill, the valid concerns that members have about its implementation, and the consequences it could have on vulnerable populations.' Their letter came as medical students sent their own to MPs, citing concerns about the Bill. The student doctors, from universities across the UK, said: 'We do not oppose dignified death – far from it. We oppose a Bill that risks offering death in place of care, that widens health inequalities, that places vulnerable patients in danger, and that reshapes the ethical foundation that our profession is built upon without any clear support. 'As future doctors, we may not yet be the voice of this profession – but we will be. And we are asking to be heard.' The Bill's sponsor, Labour MP Kim Leadbeater, has repeatedly stated that her proposed legislation has been strengthened since it was first introduced last year, insisting it is subject to robust safeguards. As it stands, the Bill would allow terminally-ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death, subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist. MPs are entitled to have a free vote on the Bill and any amendments, meaning they decide according to their conscience rather than along party lines. Prime Minister Sir Keir Starmer voted in favour of the Bill last year, but said the Government remains neutral on the issue. Both Health Secretary Wes Streeting and Justice Secretary Shabana Mahmood voted against. Last week, a majority of MPs approve a new clause, tabled by Dame Meg, to ensure medics cannot raise the topic of assisted dying with under-18s. Her separate amendment to prevent health workers from bringing up the issue with adults patients before they have raised it was voted down. A ban on advertising assisted dying should the Bill pass into law was also supported.
Business Upturn
6 hours ago
- Business Upturn
Mphasis partners with Sixfold to transform insurance underwriting capabilities
By Aman Shukla Published on June 16, 2025, 17:04 IST Mphasis has announced a strategic partnership with Sixfold, a US and UK-based AI underwriting firm reshaping how insurers assess risk. This collaboration aims to redefine the insurance underwriting landscape by harnessing the power of artificial intelligence to enhance speed, accuracy, and operational efficiency. As a certified implementation partner, Mphasis will integrate Sixfold's cutting-edge AI underwriting platform into insurers' existing systems. This platform is specifically designed for Life & Disability, Commercial P&C & Specialty, and Reinsurance sectors. By streamlining the submission intake process and providing underwriters with advanced contextual risk insights, Sixfold empowers insurance professionals to make faster, more informed decisions without compromising on accuracy. The technology significantly reduces review times—by more than half—and improves Gross Written Premium (GWP) per underwriter through intelligent risk selection. Its seamless integration into current workflows allows insurers to adopt the solution without overhauling their systems. Moreover, the platform quickly aligns with each organization's specific underwriting guidelines and risk appetite, ensuring customized and compliant decision-making. This partnership marks a major milestone in the digital transformation of insurance underwriting. With Sixfold's proven AI capabilities already in use at top-tier insurance carriers, Mphasis is positioned to drive substantial innovation in the industry. The combined expertise of both companies will enable insurers to accelerate underwriting, optimize resources, and embrace the future of AI-driven risk assessment with confidence and agility. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
